Valneva SE
PAR:VLA

Watchlist Manager
Valneva SE Logo
Valneva SE
PAR:VLA
Watchlist
Price: 1.906 EUR -0.94%
Market Cap: 309.7m EUR
Have any thoughts about
Valneva SE?
Write Note

Valneva SE
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Valneva SE
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Valneva SE
PAR:VLA
Interest Income Expense
-€35.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Interest Income Expense
€2.5m
CAGR 3-Years
N/A
CAGR 5-Years
89%
CAGR 10-Years
31%
G
Genfit SA
PAR:GNFT
Interest Income Expense
-€2.6m
CAGR 3-Years
44%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Interest Income Expense
-€8.2m
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Interest Income Expense
-€2.4m
CAGR 3-Years
-51%
CAGR 5-Years
-24%
CAGR 10-Years
-25%
OSE Immunotherapeutics SA
PAR:OSE
Interest Income Expense
-€4.4m
CAGR 3-Years
-139%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Valneva SE
Glance View

Market Cap
309.7m EUR
Industry
Biotechnology

Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

VLA Intrinsic Value
6.044 EUR
Undervaluation 68%
Intrinsic Value
Price

See Also

What is Valneva SE's Interest Income Expense?
Interest Income Expense
-35.3m EUR

Based on the financial report for Sep 30, 2024, Valneva SE's Interest Income Expense amounts to -35.3m EUR.

What is Valneva SE's Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
-29%

Over the last year, the Interest Income Expense growth was -29%.

Back to Top